Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

NCT00727233 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

NIH

Sponsor class

Conditions

Neurofibromatosis Type I
Plexiform Neurofibroma

Interventions

DRUG: Nexavar (BAY 43-9006) (Sorafenib)
DRUG: Toxicity, Pharmacokinetics
DRUG: Pharmacodynamics
DRUG: Radiographic Evaluation
DRUG: QOL assessment, Neuropsychological
DRUG: Bony Toxicity

Sponsor

National Cancer Institute (NCI)